Seroatlas · Human Serome Atlas

CR1L

Complement component receptor 1-like protein

Also known as: CR1L_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q2VPA4
Gene: CR1L
Ensembl: ENSG00000197721
Chromosome: 1
Canonical length: 569 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted in other tissues

OverviewNCBI Gene

Acts upstream of or within regulation of complement activation and regulation of complement-dependent cytotoxicity. Part of receptor complex. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

569 residues, UniProt reviewed canonical sequence.

>Q2VPA4|CR1L
     1  MAPPVRLERP FPSRRFPGLL LAALVLLLSS FSDQCNVPEW LPFARPTNLT DDFEFPIGTY
    61  LNYECRPGYS GRPFSIICLK NSVWTSAKDK CKRKSCRNPP DPVNGMAHVI KDIQFRSQIK
   121  YSCPKGYRLI GSSSATCIIS GNTVIWDNKT PVCDRIICGL PPTIANGDFT SISREYFHYG
   181  SVVTYHCNLG SRGKKVFELV GEPSIYCTSK DDQVGIWSGP APQCIIPNKC TPPNVENGIL
   241  VSDNRSLFSL NEVVEFRCQP GFGMKGPSHV KCQALNKWEP ELPSCSRVCQ PPPDVLHAER
   301  TQRDKDNFSP GQEVFYSCEP GYDLRGSTYL HCTPQGDWSP AAPRCEVKSC DDFLGQLPNG
   361  HVLFPLNLQL GAKVDFVCDE GFQLKGSSAS YCVLAGMESL WNSSVPVCER KSCETPPVPV
   421  NGMVHVITDI HVGSRINYSC TTGHRLIGHS SAECILSGNT AHWSMKPPIC QQIFCPNPPA
   481  ILNGRHTGTP LGDIPYGKEV SYTCDPHPDR GMTFNLIGES TIRRTSEPHG NGVWSSPAPR
   541  CELPVGAGSH DALIVGKFYE VFAEEFCHL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CR1L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.38
Highest tissue expression: 1.4 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 1.4 nTPM
fallopian tube: 0.1 nTPM
lymph node: 0.1 nTPM
placenta: 0.1 nTPM
spleen: 0.1 nTPM
adipose tissue: 0 nTPM

Single-cell type

erythrocyte progenitors: 126 nCPM
renal collecting duct intercalated cells: 61 nCPM
erythrocytes: 34 nCPM
podocytes: 27 nCPM
endometrial ciliated cells: 25 nCPM
epididymal clear cells: 18 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

white matter: 0.2 nTPM
cerebral cortex: 0.1 nTPM
medulla oblongata: 0.1 nTPM
pons: 0.1 nTPM
thalamus: 0.1 nTPM
amygdala: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.62
gnomAD pLI: 0
gnomAD missense Z: -0.67
DepMap mean gene effect: -0.13
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CR1L as an antibody target. Whether an autoantibody or antibody against CR1L could matter depends on whether native CR1L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CR1L is annotated as secreted, so native CR1L circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CR1L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...